JOEL LEWIS - 24 Jan 2024 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
24 Jan 2024
Transactions value $
$0
Form type
4
Filing time
07 Feb 2024, 16:48:42 UTC
Previous filing
02 Jan 2024
Next filing
04 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock Option (right to buy) Award $0 +91,000 $0.000000 91,000 24 Jan 2024 Common Stock 91,000 $1.72 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +56,000 $0.000000 56,000 24 Jan 2024 Common Stock 56,000 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025.
F3 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.
F4 Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested.